Genentech reiterated at buy by Jefferies

Jefferies & Co., Inc. analyst Adam Walsh reiterated Genentech, Inc. at a buy rating and $106 price target on the company's strong third-quarter revenues. Lucentis has become a significant driver for the company's shares, according to the analyst. Shares of the South San Francisco, Calif.-based biotherapeutic company were down $1.24, or 0.307%, at $80.45. (NYSE: DNA)

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.